Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Recommendation of “Moderate Buy” by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $16.75.

A number of brokerages have recently commented on FOLD. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Morgan Stanley reiterated an “equal weight” rating and set a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, February 20th. Wells Fargo & Company decreased their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th.

Institutional Trading of Amicus Therapeutics

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its position in shares of Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after buying an additional 458,143 shares during the last quarter. Wellington Management Group LLP increased its stake in Amicus Therapeutics by 18.8% during the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock valued at $268,112,000 after acquiring an additional 4,497,950 shares during the period. Geode Capital Management LLC raised its holdings in Amicus Therapeutics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 6,599,871 shares of the biopharmaceutical company’s stock valued at $70,499,000 after acquiring an additional 80,926 shares in the last quarter. Nuveen Asset Management LLC lifted its position in shares of Amicus Therapeutics by 4.4% in the 4th quarter. Nuveen Asset Management LLC now owns 3,807,420 shares of the biopharmaceutical company’s stock worth $35,866,000 after acquiring an additional 159,139 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Amicus Therapeutics by 5.9% in the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock worth $31,761,000 after acquiring an additional 187,652 shares during the period.

Amicus Therapeutics Stock Performance

Shares of NASDAQ FOLD opened at $7.50 on Monday. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics has a one year low of $7.39 and a one year high of $12.65. The business’s 50-day moving average price is $9.12 and its two-hundred day moving average price is $9.86. The company has a market capitalization of $2.30 billion, a P/E ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.